Relay Therapeutics, Inc. (RLAY)
收市後：
| 前收市價 | 6.35 |
| 開市 | 5.87 |
| 買盤 | 6.14 x 700 |
| 賣出價 | 6.20 x 200 |
| 今日波幅 | 5.82 - 6.21 |
| 52 週波幅 | 5.70 - 13.32 |
| 成交量 | |
| 平均成交量 | 1,220,640 |
| 市值 | 814.522M |
| Beta 值 (5 年，每月) | 1.63 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.79 |
| 業績公佈日 | 2024年5月02日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 23.05 |
Insider Monkey11 Oversold Biotech Stocks To Buy Right Now
In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip our detailed analysis of the biotech sector, you can go directly to see the 5 Oversold Biotech Stocks To Buy Right Now. Dealmaking in Biotech Healthcare has been performing well so far in 2024, and […]
- InvestorPlace
3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
Now might be a great time for investors to consider investing in precision medicine stocks. For those who don’t know, precision medicine is an approach to disease treatment and prevention that tailors medical decisions to the individual patient. It aims to provide the right treatment at the right time for the right person. This may reduce complications for the individual. Precision medicine stocks today are companies with high potential growth prospects within the healthcare sector. I’m interest
ZacksDoes Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 146.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
